Ftse Mib
33.427,07
0,04%
DAX
19.864,80
1,20%
S&P 500
6.044,77
0,77%
NASDAQ
19.218,17
0,00%
Bitcoin
96.470,67
-0,81%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Europa EU Cellectis Nom Eo 05 (ALCLS) Cellectis Nom Eo 05 (ALCLS) Notizie

Cellectis Nom Eo 05

ALCLS
1,88
-0,05 (-2,59%)
Ultimo aggiornamento: 15:17:18
Dati in Delay di 15 minuti
Borsa: Euronext
Tipo: Azione Ordinaria
Valuta: EUR

Ultime notizie

Data Ora Fonte Titolo
06/11/202422:38UKREGMonthly information on share capital and company voting..
06/11/202422:38UKREGInformation mensuelle relative au nombre total des droits de..
05/11/202422:30GLOBECellectis Presents Multiple Strategies to Enhance CAR T-cell..
05/11/202422:30UKREGCellectis Presents Multiple Strategies to Enhance CAR T-cell..
05/11/202422:30UKREGCellectis présente de multiples stratégies pour améliorer..
04/11/202422:30GLOBECellectis Provides Business Updates and Financial Results..
04/11/202422:30UKREGCellectis présente ses résultats financiers du troisième..
04/11/202422:30UKREGCellectis Provides Business Updates and Financial Results..
30/10/202421:30GLOBECellectis to Report Third Quarter 2024 Financial Results on..
30/10/202421:30UKREGCellectis to Report Third Quarter 2024 Financial Results on..
30/10/202421:30UKREGCellectis publiera ses résultats financiers du troisième..
22/10/202408:00GLOBECellectis to Present Data on TALE-Base Editors and Non-Viral..
22/10/202408:00UKREGCellectis présentera des données sur des TALE Base..
22/10/202408:00UKREGCellectis to Present Data on TALE-Base Editors and Non-Viral..
02/10/202422:30UKREGMonthly information on share capital and company voting..
02/10/202422:30UKREGInformation mensuelle relative au nombre total des droits de..
04/9/202422:30UKREGInformation mensuelle relative au nombre total des droits de..
04/9/202422:30UKREGMonthly information on share capital and company voting..
03/9/202422:30GLOBECellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells..
03/9/202422:30UKREGCellectis présente des preuves précliniques de l’efficacité..
03/9/202422:30UKREGCellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells..
26/8/202422:30UKREGCellectis Publishes a Molecular Therapy Article on a SMART..
26/8/202422:30UKREGCellectis publie un article dans Molecular Therapy sur la..
26/8/202422:30GLOBECellectis Publishes a Molecular Therapy Article on a SMART..
07/8/202408:00UKREGCellectis Appoints Dr. Adrian Kilcoyne as Chief Medical..
07/8/202408:00UKREGCellectis nomme le docteur Adrian Kilcoyne directeur médical
07/8/202408:00GLOBECellectis Appoints Dr. Adrian Kilcoyne as Chief Medical..
06/8/202422:30UKREGCellectis publie ses résultats financiers du deuxième..
06/8/202422:30UKREGCellectis Provides Financial Results for the Second Quarter..
06/8/202422:30GLOBECellectis Provides Financial Results for the Second Quarter..
05/8/202422:30UKREGInformation mensuelle relative au nombre total des droits de..
05/8/202422:30UKREGMonthly information on share capital and company voting..
01/8/202422:30UKREGFDA Grants Orphan Drug Designation to Cellectis’ CLLS52..
01/8/202422:30UKREGLa FDA accorde le statut de médicament orphelin à CLLS52..
01/8/202422:30GLOBEFDA Grants Orphan Drug Designation to Cellectis’ CLLS52..
25/7/202422:30GLOBEFDA Grants Orphan Drug and Rare Pediatric Disease..
25/7/202422:30UKREGFDA Grants Orphan Drug and Rare Pediatric Disease..
25/7/202422:30UKREGLa FDA accorde le statut de médicament orphelin et..
05/7/202422:30GLOBEMonthly information on share capital and company voting..
05/7/202422:30GLOBEInformation mensuelle relative au nombre total des droits de..
28/6/202422:30GLOBERésultats de l’Assemblée Générale Mixte de Cellectis du 28..
20/6/202422:30GLOBECellectis publie un article scientifique dévoilant trois..
12/6/202422:30GLOBECellectis Unveils a Non-Viral Gene Therapy Approach for..
05/6/202422:30GLOBEMonthly information on share capital and company voting..
05/6/202422:30GLOBEInformation mensuelle relative au nombre total des droits de..
04/6/202422:30GLOBECellectis obtient la désignation de médicament orphelin pour..
29/5/202422:30GLOBEL’ Assemblée Générale Mixte de Cellectis se tiendra le 28..
28/5/202422:30GLOBECellectis publie ses résultats financiers du premier..
27/5/202422:30GLOBECellectis to Report First Quarter 2024 Financial Results on..
16/5/202422:30GLOBEMonthly information on share capital and company voting..
Apertura: 1,89 Min: 1,88 Max: 1,92
Chiusura: 1,93

La tua Cronologia

EU
ALCLS
Cellectis Nom Eo 05
ASX
HDYOC
Hardey Resources
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network